<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/A7D96C1B-22B7-4E02-9683-66C2D5BE9549"><gtr:id>A7D96C1B-22B7-4E02-9683-66C2D5BE9549</gtr:id><gtr:name>Ningbo Number One Hospital</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/936D002F-A8D1-4A93-AE5D-825ED0903D8D"><gtr:id>936D002F-A8D1-4A93-AE5D-825ED0903D8D</gtr:id><gtr:name>University of Nottingham</gtr:name><gtr:address><gtr:line1>University Park</gtr:line1><gtr:line4>Nottingham</gtr:line4><gtr:line5>Nottinghamshire</gtr:line5><gtr:postCode>NG7 2RD</gtr:postCode><gtr:region>East Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/936D002F-A8D1-4A93-AE5D-825ED0903D8D"><gtr:id>936D002F-A8D1-4A93-AE5D-825ED0903D8D</gtr:id><gtr:name>University of Nottingham</gtr:name><gtr:address><gtr:line1>University Park</gtr:line1><gtr:line4>Nottingham</gtr:line4><gtr:line5>Nottinghamshire</gtr:line5><gtr:postCode>NG7 2RD</gtr:postCode><gtr:region>East Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/A7D96C1B-22B7-4E02-9683-66C2D5BE9549"><gtr:id>A7D96C1B-22B7-4E02-9683-66C2D5BE9549</gtr:id><gtr:name>Ningbo Number One Hospital</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/B6B6213D-3EDE-4C40-A6BE-6E8F2CB9048A"><gtr:id>B6B6213D-3EDE-4C40-A6BE-6E8F2CB9048A</gtr:id><gtr:firstName>Ian</gtr:firstName><gtr:surname>Hall</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MC_PC_12010"><gtr:id>0FE24148-8F2B-4683-BD20-95324A4A10C3</gtr:id><gtr:title>Study of common and rare genetic variants in respiratory health: the UK Biobank Lung Exome Evaluation (UK BiLEVE) consoertium</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Intramural</gtr:grantCategory><gtr:grantReference>MC_PC_12010</gtr:grantReference><gtr:abstractText>Lung function is an important indicator of respiratory health and moratlity. Measures of lung function show irreversible airway ostruction in chronic obstructive pulmonary disease (COPD), a progressive condition affecting 900,000 people in the UK. Smoking is a strong risk factor for COPD but not all smokers are equaly susceptible. Genetic approaches to understanding the mechanisms underlying the maintenance of good lung others, aim to reveal previously unknown molecular targets for drug development and to facilitiate stratified approaches to treatment and care. This project aims to detect rare genetic variants associated with lung function. Once discovered, such variants tend to exert a large effect on disease risk and provide a means to translate findings from genetic studies of lung function to clinical relevant research and development. The proposed study leverages the power of Uk Biobank and respiratory genomics to advance understanding of lung function and COPD. This project will use a customised respiratory exome chip in 50,000 UK Biobank participants, selected according to their smoking history and lung function status at baseline. This project therefore requires teh use of data (spirometry, smoking and other lifestyle factors) and DNA samples.</gtr:abstractText><gtr:technicalSummary>COPD is a long term progressive condition affecting approximately 900,000 people in the UK which accounts for ~30,000 deaths and more than &amp;pound;500m of NHS costs annually1. Management of patients with COPD includes symptomatic control, smoking cessation support where appropriate, and prevention of exacerbations, but there is no therapy that can reliably alter disease progression. Genetic approaches to understanding the mechanisms underlying COPD development and progression aim to reveal previously unknown molecular targets for drug development and unravel disease heterogeneity to facilitate stratified approaches to treatment and care. 

In this project we will identify associations between both rare and common single nucleotide polymorphisms (SNPs) and phenotypes defined by the extremes of the lung function distribution in heavy smokers and in never-smokers in the UK Biobank population (50,000 individuals in total). Specific scientific aims include:
i. To identify rare, putative functional, genetic variants associated with COPD susceptibility in heavy smokers;
ii. To identify rare genetic variants associated with resistance to tobacco smoke (by studying heavy smokers with well-preserved lung function);
iii. To identify rare genetic variants associated with COPD susceptibility among never-smokers;
iv. To identify rare genetic variants associated with high lung function measures among never-smokers;
v. To study association with these phenotypes of common SNPs (minor allele frequency (MAF)&amp;gt;5%) already reported to have shown genome-wide association with lung function;
vi. To study association with these phenotypes in almost 1500 additional independent genomic regions in which suggestive associations with lung function have been shown for common SNPs in genome-wide association studies;
vii. To identify rare genetic variants associated with tobacco addiction;
viii. To examine interactions between smoking exposure and genetic associations with lung function in this population
ix. To undertake preliminary functional work to provide additional biological insights into key associations detected, by profiling gene expression at the mRNA level and, where appropriate, at the protein level.

In addition the project has three more general aims: 

x. To provide an extensive publicly available dataset for the international research community describing associations between lung function and both common variants and intermediate/rare frequency SNPs
xi. To provide a DNA resource for UK Biobank which will cover 10% of the UK Biobank population to facilitate further genetic studies of other phenotypes
xii. To serve as an early example of the study of gene-environment (in particular, gene-smoking) interactions, which may inform the study of the joint effects of genetic and environmental factors of other traits (one of the key objectives in establishing UK Biobank).</gtr:technicalSummary><gtr:fund><gtr:end>2014-10-15</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2012-10-15</gtr:start><gtr:type>EXPENDITURE_ACTUAL</gtr:type><gtr:valuePounds>3245023</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Ningbo Number One Hospital</gtr:collaboratingOrganisation><gtr:country>China, People's Republic of</gtr:country><gtr:description>Ningbo hospitals</gtr:description><gtr:id>4DFCE61D-B37E-4706-83CC-3E38A6290DF9</gtr:id><gtr:impact>formal agreement with Ningbo number 1 hospital and planned additional academic exchanges</gtr:impact><gtr:outcomeId>56cc7cf757c909.60870458-1</gtr:outcomeId><gtr:partnerContribution>Salary, travel and living costs for visiting fellow</gtr:partnerContribution><gtr:piContribution>Provision of laboratory facilities for visiting scholar during 2015 for 12 months to study molecular genetics of lung function associated genes</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>NG paper 2017 media</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>9A045072-3AB9-413C-B5E5-15D2BF294235</gtr:id><gtr:impact>Press release and consequent media interviews including TV and radio interviews</gtr:impact><gtr:outcomeId>58b58a752fb3a4.45499737</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:year>2017</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>uk biobank meeting</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>55EE6372-6A07-415D-BC57-281A75868FB0</gtr:id><gtr:impact>UK Biobank workshop, Houses of Parliament</gtr:impact><gtr:outcomeId>58b589e64bdb22.75757846</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Policymakers/politicians</gtr:primaryAudience><gtr:year>2017</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>video for UK biobank website</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>ADA03EFD-AE1B-4653-BA5D-925B5923FCD9</gtr:id><gtr:impact>Youtube video accessed from UK Biobank website

publicity for UK biobank resource</gtr:impact><gtr:outcomeId>e2gGvum9td6</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>UK biobank regional event</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>4B9A607C-8747-4F3C-A0D0-78B84E43C5A2</gtr:id><gtr:impact>Talk to UK Biobank regional event for research participants</gtr:impact><gtr:outcomeId>56cc8091dcebe1.86563071</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Media interviews</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>0EC2AF16-8208-4CE0-99A6-3AF9FC2F2F6D</gtr:id><gtr:impact>Series of interviews following publication of Lancet Resp Med paper on UK biobank, coupled with media releases from MRC and Univeristy of Nottingham. Interviews included multiple local radio stations, Today programme, ABC News 24, San Francisco Bay radio and others</gtr:impact><gtr:outcomeId>56cc8188079d19.71351910</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>400000</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Pfizer internal funds</gtr:description><gtr:end>2016-12-02</gtr:end><gtr:fundingOrg>Pfizer Inc</gtr:fundingOrg><gtr:id>81BFC2A4-470C-4C10-B6F6-AE90AEA643F4</gtr:id><gtr:outcomeId>56cb39d25130f9.39411636</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>180000</gtr:amountPounds><gtr:country>Germany, Federal Republic of</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>industry collaboration,</gtr:description><gtr:end>2017-10-02</gtr:end><gtr:fundingOrg>Boehringer Ingelheim</gtr:fundingOrg><gtr:id>8F527C95-38B7-4385-A226-E5EE7A6A3D4E</gtr:id><gtr:outcomeId>58b58926727396.46490852</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2016-11-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>50000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>EUR</gtr:currCode><gtr:currCountryCode>Austria</gtr:currCountryCode><gtr:currLang>de_AT</gtr:currLang><gtr:description>Chiesi foundation</gtr:description><gtr:end>2014-07-02</gtr:end><gtr:fundingOrg>Chiesi</gtr:fundingOrg><gtr:id>A7187E07-88B8-4319-8461-524CC43E51CE</gtr:id><gtr:outcomeId>csT6Ybx8pvA</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2013-07-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>540000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Pfizer internal funds</gtr:description><gtr:end>2014-12-02</gtr:end><gtr:fundingOrg>Pfizer Ltd</gtr:fundingOrg><gtr:id>027560F3-38D8-43CD-8FC5-02B46FB1153A</gtr:id><gtr:outcomeId>SpV67e233Ks</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2012-12-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>23600000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>NIHR Biomedical Research Centre</gtr:department><gtr:description>Nottingham BRC</gtr:description><gtr:end>2022-03-02</gtr:end><gtr:fundingOrg>National Institute for Health Research</gtr:fundingOrg><gtr:id>1708B794-1D14-4997-831D-2EB201685350</gtr:id><gtr:outcomeId>58b58b284f2e56.68576964</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2017-04-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs><gtr:researchDatabaseAndModelOutput><gtr:description>As above: provosion of genotype data on 50,000 individuals in UK biobank</gtr:description><gtr:id>F67CC1F8-0FFA-402E-AC18-D0A2ADD80F39</gtr:id><gtr:impact>Publications in preparation.</gtr:impact><gtr:outcomeId>54661aed0c8d89.80236496</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Genotype data for UK Biobank</gtr:title><gtr:type>Database/Collection of data</gtr:type><gtr:yearFirstProvided>2014</gtr:yearFirstProvided></gtr:researchDatabaseAndModelOutput></gtr:researchDatabaseAndModelOutputs><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>genotyping platofrm combining exome and genome wide content for use if UK and Caucasian populations</gtr:description><gtr:id>8A8B698A-8E39-4C6D-A3A7-11C4B576DFC9</gtr:id><gtr:impact>Genotyping ongoing for several studies with this platform will result in outputs in 2014/15. Contribution to UK Biobank genotyping platform</gtr:impact><gtr:outcomeId>DVEABZXNKUE</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>UK BiLEVE and UK biobank genotyping chips</gtr:title><gtr:type>Technology assay or reagent</gtr:type><gtr:yearFirstProvided>2014</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>322A7E80-E165-445F-B199-A55FB66864F6</gtr:id><gtr:title>Novel insights into the genetics of smoking behaviour, lung function, and chronic obstructive pulmonary disease (UK BiLEVE): a genetic association study in UK Biobank.</gtr:title><gtr:parentPublicationTitle>The Lancet. Respiratory medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a94bd817e0697ab1ede1ac552afec188"><gtr:id>a94bd817e0697ab1ede1ac552afec188</gtr:id><gtr:otherNames>Wain LV</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>2213-2600</gtr:issn><gtr:outcomeId>56cb3caf034f19.21004212</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EAAAF4D6-8A74-4E58-9005-5574FE48DA3E</gtr:id><gtr:title>Use of FEV1 as a measure of lung health in the UK BiLEVE study - Authors' reply.</gtr:title><gtr:parentPublicationTitle>The Lancet. Respiratory medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a94bd817e0697ab1ede1ac552afec188"><gtr:id>a94bd817e0697ab1ede1ac552afec188</gtr:id><gtr:otherNames>Wain LV</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>2213-2600</gtr:issn><gtr:outcomeId>56cb3bed07fd72.36093064</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D64BC9B6-1BF3-4012-B971-705914BBD9FC</gtr:id><gtr:title>Haplotype estimation for biobank-scale data sets.</gtr:title><gtr:parentPublicationTitle>Nature genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fe4a6e3a0091b5187b331fe07ed7abac"><gtr:id>fe4a6e3a0091b5187b331fe07ed7abac</gtr:id><gtr:otherNames>O'Connell J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1061-4036</gtr:issn><gtr:outcomeId>585d6ae31e94e7.83222144</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>94661A1B-8F08-4272-BBE0-3E1760FFEE70</gtr:id><gtr:title>Human CCL3L1 copy number variation, gene expression, and the role of the CCL3L1-CCR5 axis in lung function</gtr:title><gtr:parentPublicationTitle>Wellcome Open Research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/dd81dbe2e90b99450d3b91dcbf111547"><gtr:id>dd81dbe2e90b99450d3b91dcbf111547</gtr:id><gtr:otherNames>Adewoye A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:outcomeId>5a995f431ccc09.37026984</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>276DB85D-10CC-4DF0-9E3F-EEBCDED62994</gtr:id><gtr:title>Genes associated with polymorphic variants predicting lung function are differentially expressed during human lung development.</gtr:title><gtr:parentPublicationTitle>Respiratory research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/773f51694c81fa0805c69c6e23f77df1"><gtr:id>773f51694c81fa0805c69c6e23f77df1</gtr:id><gtr:otherNames>Miller S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1465-9921</gtr:issn><gtr:outcomeId>585d3c94ae0fe4.97689605</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>821393D2-EFD2-41F2-9C9E-250013DC0550</gtr:id><gtr:title>Age at menarche and lung function: a Mendelian randomization study.</gtr:title><gtr:parentPublicationTitle>European journal of epidemiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a65fc532df4d803bbe2d3078add87301"><gtr:id>a65fc532df4d803bbe2d3078add87301</gtr:id><gtr:otherNames>Gill D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0393-2990</gtr:issn><gtr:outcomeId>5aa2af9c21dda2.79197716</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0728D51C-5F9B-492B-8D5B-C35D4AED103C</gtr:id><gtr:title>Genome-wide association study of copy number variation with lung function identifies a novel signal of association near BANP for forced vital capacity.</gtr:title><gtr:parentPublicationTitle>BMC genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d6689aa270ed9863ccd7865430daf5e7"><gtr:id>d6689aa270ed9863ccd7865430daf5e7</gtr:id><gtr:otherNames>Shrine N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1471-2156</gtr:issn><gtr:outcomeId>585d6aea3010f5.41388884</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4501E4D8-CD17-4D96-8A53-FB6DAFA777DA</gtr:id><gtr:title>Integrative pathway genomics of lung function and airflow obstruction.</gtr:title><gtr:parentPublicationTitle>Human molecular genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9c05559d7335b9b762af57cf666e411c"><gtr:id>9c05559d7335b9b762af57cf666e411c</gtr:id><gtr:otherNames>Gharib SA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0964-6906</gtr:issn><gtr:outcomeId>56cb3caf6dbe91.54972818</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BA9955E3-5FAF-4FD8-88BE-B7304F3C3618</gtr:id><gtr:title>Genetic loci associated with chronic obstructive pulmonary disease overlap with loci for lung function and pulmonary fibrosis.</gtr:title><gtr:parentPublicationTitle>Nature genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/844cdfad3fa538e575be3a8c1298d1dd"><gtr:id>844cdfad3fa538e575be3a8c1298d1dd</gtr:id><gtr:otherNames>Hobbs BD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1061-4036</gtr:issn><gtr:outcomeId>5aa2af9c979779.46436138</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2A1A4422-6761-4413-91D1-DD3916E75CC6</gtr:id><gtr:title>Genetic variants affecting cross-sectional lung function in adults show little or no effect on longitudinal lung function decline.</gtr:title><gtr:parentPublicationTitle>Thorax</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e0a76b233d1a49c41cd89d0a00a6574f"><gtr:id>e0a76b233d1a49c41cd89d0a00a6574f</gtr:id><gtr:otherNames>John C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0040-6376</gtr:issn><gtr:outcomeId>5aa2af9cc37af1.54739682</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B434F28C-F49C-4FD1-A9F0-4F15DCE24D56</gtr:id><gtr:title>Molecular mechanisms underlying variations in lung function: a systems genetics analysis.</gtr:title><gtr:parentPublicationTitle>The Lancet. Respiratory medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/50b8ae389974a10a5749dc28b02da493"><gtr:id>50b8ae389974a10a5749dc28b02da493</gtr:id><gtr:otherNames>Obeidat M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>2213-2600</gtr:issn><gtr:outcomeId>56cb3caf376e57.44938954</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D0BB7738-287F-4198-8C25-287337F5C6F4</gtr:id><gtr:title>Exome-wide analysis of rare coding variation identifies novel associations with COPD and airflow limitation in MOCS3, IFIT3 and SERPINA12.</gtr:title><gtr:parentPublicationTitle>Thorax</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/de105329f79332d794fb42220954ac91"><gtr:id>de105329f79332d794fb42220954ac91</gtr:id><gtr:otherNames>Jackson VE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0040-6376</gtr:issn><gtr:outcomeId>585d6ae6db1dc2.97437171</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>52FFC81B-8BF1-4553-9192-28C29F6760E8</gtr:id><gtr:title>Sixteen new lung function signals identified through 1000 Genomes Project reference panel imputation.</gtr:title><gtr:parentPublicationTitle>Nature communications</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/346132cc73b072383cbff8aaa61b0286"><gtr:id>346132cc73b072383cbff8aaa61b0286</gtr:id><gtr:otherNames>Soler Artigas M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>2041-1723</gtr:issn><gtr:outcomeId>56cb3caebf6f73.10108202</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MC_PC_12010</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>E3CED108-9B11-45C4-A81B-3730D641CA68</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Respiratory</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>CF950C9A-DB16-4E23-8AEB-94548777BCA1</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>1.1  Normal biological development and functioning</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>